Visible gets $30 million equity injection:
This article was originally published in Clinica
Executive Summary
Visible Genetics, an HIV diagnostics company which earlier this month announced restated sales and increased losses for the first quarter (see Clinica No 866, p 12), has secured a $30 million equity investment from EM Warburg Pincus. Warburg will get preference shares and a board seat on the company, while Toronto-based Visible will use the money to commercialise HIV, hepatitis B and C and tuberculosis genotyping diagnostics.